Recode Therapeutic News Today

Another $80M: mRNA biotech ReCode matches 2020 series A with Pfizer, Sanofi money for cystic fibrosis trial

October 21, 2021

ReCode Therapeutics is back with its second $80 million financing round, this time a series B from Pfizer, Sanofi and VC shops, to bring its lead programs into human trials. Up first are cystic fibrosis and primary ciliary dyskinesia, another lung disease.

United States David Lockhart Big Pharma Recode Therapeutic Fierce Biotech Recode Therapeutics

Source: fiercebiotech.com

Navigation

Recode Therapeutic News Today

Intellia, ReCode partner on genetic medicines for cystic fibrosis

Another $80M: mRNA biotech ReCode matches 2020 series A with Pfizer, Sanofi money for cystic fibrosis trial

Explore More Categories